Case Reports
Vol. 5 No. 3 (2026): In memory of Armando D’Angelo
A case of inadvertent overdose with argatroban in a 13-month-old toddler in the cardiac catheterization lab setting
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 28 August 2026
0
Views
0
Downloads
Authors
A case-report is presented of a toddler who received an overdose of argatroban in the cardiac catheterization lab setting due to suspected heparin induced thrombocytopenia. This is the highest known overdose of argatroban in terms of dose-to-weight ratio. The overdose was treated and the patient was recovered in the intensive care unit. Two other adult case reports are discussed and key lessons and suggestions to improve safety for argatroban and for heparin induced thrombocytopenia patients in the hospital setting are also presented.
Downloads
Download data is not yet available.
Citations
1. Cuker A. Heparin-induced thrombocytopenia (HIT) in 2011: an epidemic of overdiagnosis. Thromb Haemost 2011;106:993-4.
2. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2018;2:3360-92.
3. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e495S-530S.
4. May J, Cuker A. Practical guide to the diagnosis and management of heparin-induced thrombocytopenia. Hematology Am Soc Hematol Educ Program 2024;2024: 388-95.
5. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:340S-80S.
6. Vakil NH, Kanaan AO, Donovan JL. Heparin-induced thrombocytopenia in the pediatric population: a review of current literature. J Pediatr Pharmacol Ther 2012;17:12-30.
7. Argatroban drug information. In: Micromedex. Ann Arbor (MI): Truven Health Analytics.
8. Lee KR, Phelps SJ, Hagemann TM. Argatroban. In: Pediatric Injectable Drugs: the Teddy Bear Book. 12th ed. Bethesda (MD) : American Society of Health-System Pharmacists ; 2024.
9. Argatroban prescribing information. Silver Spring (MD): US Food and Drug Administration; 2026. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212035s003lbl.pdf
10. Mahat KC, Sedhai YR, Krishnan P. Argatroban. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2026. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555971/
11. Knoblauch R, Pollak ES, Russell JE. Toxicity of argatroban overdose in a 65-year-old man. Am J Hematol 2005;79:248-9.
12. Nicolas D, Nicolas S, Hodgens A, Reed M. Heparin-induced thrombocytopenia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2026. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482330/
13. Patriarcheas V, Pikoulas A, Kostis M, Charpidou A, Dimakakos E. Heparin-induced thrombocytopenia: pathophysiology, diagnosis and management. Cureus 2020;12:e7385.
14. Yee AJ, Kuter DJ. Successful recovery after an overdose of argatroban. Ann Pharmacother 2006;40:336-9.
15. Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:652-4.
16. Latham GJ, Jefferis Kirk C, Falconer A, et al. Challenging argatroban management of a child on extracorporeal support and subsequent heart transplant. Semin Cardiothorac Vasc Anesth 2016;20:168-74.
17. Babuin L, Pengo V. Argatroban in the management of heparin-induced thrombocytopenia. Vasc Health Risk Manag
2010;6:813-9.
18. Fanikos J, Fiumara K, Baroletti S, et al. Impact of smart infusion technology on administration of anticoagulants (unfractionated heparin, argatroban, lepirudin, and bivalirudin). Am J Cardiol 2007;99:1002-5.
Ethics Approval
This article does not contain any studies with human participants or animals performed by the author. The case report depicts true care in a hospital setting and subsequent quality improvement strategiesData Availability Statement
All data is included.
How to Cite
1.
Mahan CE. A case of inadvertent overdose with argatroban in a 13-month-old toddler in the cardiac catheterization lab setting. Bleeding Thromb Vasc Biol [Internet]. 2026 Aug. 28 [cited 2026 Aug. 28];5(3). Available from: https://www.btvb.org/btvb/article/view/567
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
